Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.31 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21455609 | 0.94 | UCHL1 (0.31) | UCHL1 | |
| SCHEMBL25911922 | 0.91 | EGFR (0.32) | EGFRAKR1C3AKR1C2UCHL1 | |
| SCHEMBL21562070 | 0.89 | MAOB (0.31) | EGFR | |
| SCHEMBL23241659 | 0.88 | KDM4E (0.36) | EGFRUCHL1 | |
| SCHEMBL24200307 | 0.88 | SMN1; SMN2 (0.33) | AKR1C3AKR1C2 | |
| SCHEMBL21455145 | 0.87 | TBXAS1 (0.36) | EGFRAKR1C3AKR1C2 | |
| SCHEMBL25894394 | 0.87 | TBXAS1 (0.36) | EGFRAKR1C3AKR1C2 | |
| SCHEMBL24200175 | 0.84 | KDM4E (0.31) | EGFRAKR1C3AKR1C2UCHL1 | |
| SCHEMBL21562075 | 0.83 | MEN1 (0.33) | — | |
| SCHEMBL25908893 | 0.81 | PKM (0.33) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230072867-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-03-09 | — | — | US | disclosed |
| US-11370774-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230072867-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | C9, C5, C1QBP | EGFR 2714/4885AKR1C3 180/4885AKR1C2 1442/4885 |
| US-11370774-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | C9, C5, C1QBP | EGFR 2714/4885AKR1C3 180/4885AKR1C2 1442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.